Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: Immediate benefits are not maintained after discontinuation of infliximab

Clinical and Experimental Rheumatology

Volumn 23, Issue 2, 2005, Pages 145-151

  Covelli, Michele ^a   Scioscia, Crescenzio ^a   Iannone, Florenzo ^a   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti TNF ; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; LOW DRUG DOSE; MALE; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18644367153     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. GLADMAN DD, FAREWELL VT, NADEAU C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22: 675-9.
2. ESPINOZA LR, ZAKRAOUI L, ESPINOZA CG et al.: Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872-7.
3. CUTOLO M, SERIOLO B, PIZZORNI C, CRAVIOTTO C, SULLI A: Methotrexate in psoriatic arthritis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S76-S80.
4. SALVARANI C, CANTINI F, OLIVIERI I: Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S71-S75.
5. SALVARANI C, OLIVIERI I, CANTINI F, MACCHIONI L, BOIARDI L: Psoriatic arthritis. Curr Opin Rheumatol 1998; 10: 299-305.
6. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-563.
7. RITCHLIN C, HAAS-SMITH SA, HICKS D, CAPPUCCIO J, OSTERLAND CK, LOONEY RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
8. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-33.
9. Van den BOSCH F, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
10. KRUITHOF E, Van den BOSCH F, BAETEN D et al.: Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207-12.
11. ANTONI C, DECHANT C, HANNS-MARTIN LORENZ PD et al.: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-12.
12. PROVENZANO G, TERMINI A, LE MOLI C, RINALDI F: Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: An open pilot study. Ann Rheum Dis 2003; 62: 680-681.
13. SALVARANI C, CANTINI F, OLIVIERI I et al.: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49: 541-5.
14. DOUGADOS M, van der LS, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
15. HUSTED JA, GLADMAN DD, LONG JA, FAREWELL VT: A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995; 13: 439-43.
16. BLACKMORE MG, GLADMAN DD, HUSTED J, LONG JA, FAREWELL VT: Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 886-93.
17. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
18. CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2004-12.
19. van GESTEL AM, PREVOO ML, 't HOF MA, van RIJSWIJK MH, van de PUTTE LB, van RIEL PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
20. ANTONI C, KAVANAUGH A, KIRKHAM B et al.: The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2002; 46 (Suppl. 9): S985 (abstract).
21. FELETAR M, BROCKBANK JE, SCHENTAG CT, LAPP V, GLADMAN DD: Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63: 156-61.